PATENT CLAIM ANALYSIS

Application Number: 16059121
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-07
Patent Classification: ["514", "04400A"]

Abstract:
The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).

Claim (Index 4):
An isolated nucleic acid comprising:\n (a) a first region encoding one or more first miRNAs comprising a nucleic acid having sufficient sequence complementary with an endogenous mRNA of a subject to hybridize with and inhibit expression of the endogenous mRNA, wherein the endogenous mRNA encodes a first protein; and (b) a second region encoding an exogenous mRNA that encodes a second protein, wherein the second protein has an amino acid sequence that is at least 85% identical to the first protein, wherein the one or more first miRNAs do not comprise a nucleic acid having sufficient sequence complementary to hybridize with and inhibit expression of the exogenous mRNA, and wherein the first region is positioned downstream of a portion of the second region encoding the poly-A tail of the exogenous mRNA.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 96.0
- Lexical Diversity: 1.08
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14113118', '15098833', '13642719', '14445670', '15705909']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.75137606142231
- 35 USC 102 Novelty (BERT): 0.7146522445290723
- Combined Prediction Score: 0.7477036797329862
- Mean Citation Score: 539.9870999999998
- Max Citation Score: 791.0799599999997
- Similarity Product: 739.7795778197334

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test